{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,8]],"date-time":"2026-11-08T00:34:46Z","timestamp":1794098086603,"version":"4.8.0"},"reference-count":41,"publisher":"Elsevier BV","issue":"13","license":[{"start":{"date-parts":[[2017,9,1]],"date-time":"2017-09-01T00:00:00Z","timestamp":1504224000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2018,9,26]],"date-time":"2018-09-26T00:00:00Z","timestamp":1537920000000},"content-version":"vor","delay-in-days":390,"URL":"http:\/\/www.elsevier.com\/open-access\/userlicense\/1.0\/"}],"content-domain":{"domain":["clinicalkey.jp","onlinejacc.org","clinicalkey.com","clinicalkey.es","clinicalkey.fr","clinicalkey.com.au","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of the American College of Cardiology"],"published-print":{"date-parts":[[2017,9]]},"DOI":"10.1016\/j.jacc.2017.07.783","type":"journal-article","created":{"date-parts":[[2017,9,18]],"date-time":"2017-09-18T15:00:24Z","timestamp":1505746824000},"page":"1543-1554","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":81,"title":["Adherence Tradeoff to Multiple Preventive Therapies and All-Cause Mortality After Acute Myocardial Infarction"],"prefix":"10.1016","volume":"70","author":[{"given":"Maarit J.","family":"Korhonen","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jennifer G.","family":"Robinson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Izabela E.","family":"Annis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ryan P.","family":"Hickson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J. Simon","family":"Bell","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Juha","family":"Hartikainen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gang","family":"Fang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.jacc.2017.07.783_bib1","doi-asserted-by":"crossref","first-page":"177","DOI":"10.1001\/jama.297.2.177","article-title":"Relationship between adherence to evidence-based pharmacotherapy and long-term mortality after acute myocardial infarction","volume":"297","author":"Rasmussen","year":"2007","journal-title":"JAMA"},{"key":"10.1016\/j.jacc.2017.07.783_bib2","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1016\/j.ahj.2013.09.014","article-title":"Untangling the relationship between medication adherence and post-myocardial infarction outcomes: medication adherence and clinical outcomes","volume":"167","author":"Choudhry","year":"2014","journal-title":"Am Heart J"},{"key":"10.1016\/j.jacc.2017.07.783_bib3","doi-asserted-by":"crossref","first-page":"1093","DOI":"10.1002\/pds.3840","article-title":"Effect of adherence to evidence-based therapy after acute myocardial infarction on all-cause mortality","volume":"24","author":"Hamood","year":"2015","journal-title":"Pharmacoepidemiology Drug Saf"},{"key":"10.1016\/j.jacc.2017.07.783_bib4","doi-asserted-by":"crossref","first-page":"789","DOI":"10.1016\/j.jacc.2016.06.005","article-title":"Assessing the impact of medication adherence on long-term cardiovascular outcomes","volume":"68","author":"Bansilal","year":"2016","journal-title":"J\u00a0Am Coll Cardiol"},{"key":"10.1016\/j.jacc.2017.07.783_bib5","doi-asserted-by":"crossref","first-page":"754","DOI":"10.1161\/CIRCULATIONAHA.113.002658","article-title":"Racial\/ethnic and gender gaps in the use of and adherence to evidence-based preventive therapies among elderly Medicare Part D beneficiaries after acute myocardial infarction","volume":"129","author":"Lauffenburger","year":"2014","journal-title":"Circulation"},{"key":"10.1016\/j.jacc.2017.07.783_bib6","doi-asserted-by":"crossref","first-page":"62","DOI":"10.1016\/j.ahj.2015.03.019","article-title":"Persistence with secondary prevention medications after acute myocardial infarction: Insights from the TRANSLATE-ACS study","volume":"170","author":"Mathews","year":"2015","journal-title":"Am Heart J"},{"key":"10.1016\/j.jacc.2017.07.783_bib7","doi-asserted-by":"crossref","first-page":"2940","DOI":"10.1093\/eurheartj\/eht295","article-title":"Adherence to cardiovascular therapy: a meta-analysis of prevalence and clinical consequences","volume":"34","author":"Chowdhury","year":"2013","journal-title":"Eur Heart J"},{"key":"10.1016\/j.jacc.2017.07.783_bib8","doi-asserted-by":"crossref","first-page":"E449","DOI":"10.1503\/cmaj.131807","article-title":"Lifestyle factors as predictors of nonadherence to statin therapy among patients with and without cardiovascular comorbidities","volume":"186","author":"Halava","year":"2014","journal-title":"CMAJ"},{"key":"10.1016\/j.jacc.2017.07.783_bib9","doi-asserted-by":"crossref","first-page":"243","DOI":"10.1007\/s00228-014-1793-8","article-title":"Does age modify the relationship between adherence to secondary prevention medications and mortality after acute myocardial infarction? A nested case-control study","volume":"71","author":"Lenzi","year":"2015","journal-title":"Eur J Clin Pharmacol"},{"key":"10.1016\/j.jacc.2017.07.783_bib10","doi-asserted-by":"crossref","first-page":"989","DOI":"10.1093\/gerona\/glv013","article-title":"Polypharmacy among adults aged 65 years and older in the United States: 1988-2010","volume":"70","author":"Charlesworth","year":"2015","journal-title":"J\u00a0Gerontol A Biol Sci Med Sci"},{"key":"10.1016\/j.jacc.2017.07.783_bib11","doi-asserted-by":"crossref","first-page":"2261","DOI":"10.1111\/jgs.13153","article-title":"Health outcomes associated with polypharmacy in community-dwelling older adults: a systematic review","volume":"62","author":"Fried","year":"2014","journal-title":"J\u00a0Am Geriatr Soc"},{"key":"10.1016\/j.jacc.2017.07.783_bib12","first-page":"814","article-title":"The implications of therapeutic complexity on adherence to cardiovascular medications","volume":"171","author":"Choudhry","year":"2011","journal-title":"Arch Intern Med"},{"key":"10.1016\/j.jacc.2017.07.783_bib13","doi-asserted-by":"crossref","first-page":"747","DOI":"10.1111\/jgs.14682","article-title":"Clinical outcomes associated with medication regimen complexity in older people: a systematic review","volume":"65","author":"Wimmer","year":"2017","journal-title":"J\u00a0Am Geriatr Soc"},{"key":"10.1016\/j.jacc.2017.07.783_bib14","doi-asserted-by":"crossref","first-page":"1189","DOI":"10.1002\/pds.1671","article-title":"Trends in adherence to secondary prevention medications in elderly post-myocardial infarction patients","volume":"17","author":"Choudhry","year":"2008","journal-title":"Pharmacoepidemiol Drug Saf"},{"key":"10.1016\/j.jacc.2017.07.783_bib15","doi-asserted-by":"crossref","first-page":"1153","DOI":"10.1093\/eurheartj\/ehi705","article-title":"Long-term compliance with beta-blockers, angiotensin-converting enzyme inhibitors, and statins after acute myocardial infarction","volume":"27","author":"Gislason","year":"2006","journal-title":"Eur Heart J"},{"key":"10.1016\/j.jacc.2017.07.783_bib16","doi-asserted-by":"crossref","first-page":"485","DOI":"10.1016\/j.jacc.2012.11.018","volume":"61","author":"O'Gara","year":"2013","journal-title":"J\u00a0Am Coll Cardiol"},{"key":"10.1016\/j.jacc.2017.07.783_bib17","doi-asserted-by":"crossref","first-page":"e179","DOI":"10.1016\/j.jacc.2013.01.014","volume":"61","author":"Anderson","year":"2013","journal-title":"J\u00a0Am Coll Cardiol"},{"key":"10.1016\/j.jacc.2017.07.783_bib18","doi-asserted-by":"crossref","first-page":"526","DOI":"10.1111\/jgs.13953","article-title":"Association between preadmission functional status and use and effectiveness of secondary prevention medications in elderly survivors of acute myocardial infarction","volume":"64","author":"Chrischilles","year":"2016","journal-title":"J\u00a0Am Geriatr Soc"},{"key":"10.1016\/j.jacc.2017.07.783_bib19","doi-asserted-by":"crossref","first-page":"59","DOI":"10.1002\/pds.3719","article-title":"Using\u00a0claims data to predict dependency in activities of daily living as a proxy for frailty","volume":"24","author":"Faurot","year":"2015","journal-title":"Pharmacoepidemiol Drug Saf"},{"key":"10.1016\/j.jacc.2017.07.783_bib20","doi-asserted-by":"crossref","first-page":"95","DOI":"10.1016\/j.cmpb.2007.07.010","article-title":"A\u00a0SAS macro for estimation of direct adjusted survival curves based on a stratified Cox regression model","volume":"88","author":"Zhang","year":"2007","journal-title":"Comput Methods Programs Biomed"},{"key":"10.1016\/j.jacc.2017.07.783_bib21","doi-asserted-by":"crossref","first-page":"1842","DOI":"10.1001\/archinte.166.17.1842","article-title":"Impact of medication therapy discontinuation on mortality after myocardial infarction","volume":"166","author":"Ho","year":"2006","journal-title":"Arch Intern Med"},{"key":"10.1016\/j.jacc.2017.07.783_bib22","doi-asserted-by":"crossref","first-page":"363","DOI":"10.1016\/j.acvd.2010.05.003","article-title":"Evidence-based pharmacotherapy after myocardial infarction in France: adherence-associated factors and relationship with 30-month mortality and rehospitalization","volume":"103","author":"Tuppin","year":"2010","journal-title":"Arch Cardiovasc Dis"},{"key":"10.1016\/j.jacc.2017.07.783_bib23","doi-asserted-by":"crossref","first-page":"1340","DOI":"10.1001\/jama.2012.12559","article-title":"\u00df-Blocker use and clinical outcomes in stable outpatients with and without coronary artery disease","volume":"308","author":"Bangalore","year":"2012","journal-title":"JAMA"},{"key":"10.1016\/j.jacc.2017.07.783_bib24","doi-asserted-by":"crossref","first-page":"96","DOI":"10.1016\/j.ehj.2003.06.011","article-title":"Is an additional post-myocardial infarction beta-blocker trial required in the era of early revascularization?","volume":"25","author":"Mickley","year":"2004","journal-title":"Eur Heart J"},{"key":"10.1016\/j.jacc.2017.07.783_bib25","doi-asserted-by":"crossref","first-page":"2705","DOI":"10.1016\/j.jacc.2016.03.522","article-title":"Early intravenous beta-blockers in patients with ST-segment elevation myocardial infarction before primary percutaneous coronary intervention","volume":"67","author":"Roolvink","year":"2016","journal-title":"J\u00a0Am Coll Cardiol"},{"key":"10.1016\/j.jacc.2017.07.783_bib26","doi-asserted-by":"crossref","first-page":"293","DOI":"10.1056\/NEJM199108013250501","article-title":"Effect of enalapril on survival in patients with reduced left ventricular ejection fractions and congestive heart failure","volume":"325","author":"Yusuf","year":"1991","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.jacc.2017.07.783_bib27","doi-asserted-by":"crossref","first-page":"1429","DOI":"10.1056\/NEJM198706043162301","article-title":"Effects of enalapril on mortality in severe congestive heart failure. Results of the Cooperative North Scandinavian Enalapril Survival Study (CONSENSUS)","volume":"316","year":"1987","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.jacc.2017.07.783_bib28","doi-asserted-by":"crossref","first-page":"2248","DOI":"10.1056\/NEJMoa0706201","article-title":"Rosuvastatin in older patients with systolic heart failure","volume":"357","author":"Kjekshus","year":"2007","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.jacc.2017.07.783_bib29","doi-asserted-by":"crossref","first-page":"1231","DOI":"10.1016\/S0140-6736(08)61240-4","article-title":"Effect of rosuvastatin in patients with chronic heart failure (the GISSI-HF trial): a randomised, double-blind, placebo-controlled trial","volume":"372","author":"Tavazzi","year":"2008","journal-title":"Lancet"},{"key":"10.1016\/j.jacc.2017.07.783_bib30","doi-asserted-by":"crossref","first-page":"2001","DOI":"10.1016\/S0140-6736(99)04440-2","article-title":"Effect of metoprolol CR\/XL in chronic heart failure: Metoprolol CR\/XL Randomised Intervention Trial in-Congestive Heart Failure (MERIT-HF)","volume":"353","year":"1999","journal-title":"Lancet"},{"key":"10.1016\/j.jacc.2017.07.783_bib31","doi-asserted-by":"crossref","first-page":"1651","DOI":"10.1056\/NEJM200105313442201","article-title":"Effect of carvedilol on survival in severe chronic heart failure","volume":"344","author":"Packer","year":"2001","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jacc.2017.07.783_bib32","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1016\/S0140-6736(98)11181-9","article-title":"The Cardiac Insufficiency Bisoprolol Study II (CIBIS-II): a randomised trial","volume":"353","year":"1999","journal-title":"Lancet"},{"key":"10.1016\/j.jacc.2017.07.783_bib33","doi-asserted-by":"crossref","first-page":"215","DOI":"10.1093\/eurheartj\/ehi115","article-title":"Randomized trial to determine the effect of nebivolol on mortality and cardiovascular hospital admission in elderly patients with heart failure (SENIORS)","volume":"26","author":"Flather","year":"2005","journal-title":"Eur Heart J"},{"key":"10.1016\/j.jacc.2017.07.783_bib34","doi-asserted-by":"crossref","first-page":"773","DOI":"10.1001\/jamainternmed.2014.348","article-title":"Effect of angiotensin-converting enzyme inhibitors and angiotensin II receptor blockers on all-cause mortality, cardiovascular deaths, and cardiovascular events in patients with diabetes mellitus: a meta-analysis","volume":"174","author":"Cheng","year":"2014","journal-title":"JAMA Intern Med"},{"key":"10.1016\/j.jacc.2017.07.783_bib35","doi-asserted-by":"crossref","first-page":"117","DOI":"10.1016\/S0140-6736(08)60104-X","article-title":"Efficacy of cholesterol-lowering therapy in 18,686 people with diabetes in 14 randomised trials of statins: a meta-analysis","volume":"371","author":"Kearney","year":"2008","journal-title":"Lancet"},{"key":"10.1016\/j.jacc.2017.07.783_bib36","doi-asserted-by":"crossref","first-page":"97","DOI":"10.2337\/diaclin.33.2.97","article-title":"Standards of Medical Care in Diabetes\u20142015 abridged for primary care providers","volume":"33","year":"2015","journal-title":"Clin Diabetes"},{"key":"10.1016\/j.jacc.2017.07.783_bib37","doi-asserted-by":"crossref","first-page":"507","DOI":"10.1001\/jama.2013.284427","article-title":"2014 evidence-based guideline for the management of high blood pressure in adults: report from the panel members appointed to the Eighth Joint National Committee (JNC 8)","volume":"311","author":"James","year":"2014","journal-title":"JAMA"},{"key":"10.1016\/j.jacc.2017.07.783_bib38","doi-asserted-by":"crossref","first-page":"114","DOI":"10.1161\/CIRCULATIONAHA.106.179294","article-title":"Primary prevention of cardiovascular diseases in people with diabetes mellitus: a scientific statement from the American Heart Association and the American Diabetes Association","volume":"115","author":"Buse","year":"2007","journal-title":"Circulation"},{"key":"10.1016\/j.jacc.2017.07.783_bib39","doi-asserted-by":"crossref","first-page":"254","DOI":"10.1001\/jamainternmed.2016.7701","article-title":"Association of \u00df-blockers with functional outcomes, death, and rehospitalization in older nursing home residents after acute myocardial infarction","volume":"177","author":"Steinman","year":"2017","journal-title":"JAMA Intern Med"},{"key":"10.1016\/j.jacc.2017.07.783_bib40","doi-asserted-by":"crossref","first-page":"1254","DOI":"10.1016\/j.amjcard.2007.05.057","article-title":"A\u00a0meta-analysis of 94,492 patients with hypertension treated with beta blockers to determine the risk of new-onset diabetes mellitus","volume":"100","author":"Bangalore","year":"2007","journal-title":"Am J Cardiol"},{"key":"10.1016\/j.jacc.2017.07.783_bib41","doi-asserted-by":"crossref","first-page":"201","DOI":"10.1016\/S0140-6736(07)60108-1","article-title":"Incident diabetes in clinical trials of antihypertensive drugs: a network meta-analysis","volume":"369","author":"Elliott","year":"2007","journal-title":"Lancet"}],"container-title":["Journal of the American College of Cardiology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0735109717391465?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0735109717391465?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2018,9,25]],"date-time":"2018-09-25T22:25:11Z","timestamp":1537914311000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0735109717391465"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,9]]},"references-count":41,"journal-issue":{"issue":"13","published-print":{"date-parts":[[2017,9]]}},"alternative-id":["S0735109717391465"],"URL":"https:\/\/doi.org\/10.1016\/j.jacc.2017.07.783","relation":{},"ISSN":["0735-1097"],"issn-type":[{"value":"0735-1097","type":"print"}],"subject":[],"published":{"date-parts":[[2017,9]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Adherence Tradeoff to Multiple Preventive Therapies and All-Cause Mortality After Acute Myocardial Infarction","name":"articletitle","label":"Article Title"},{"value":"Journal of the American College of Cardiology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jacc.2017.07.783","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2017 by the American College of Cardiology Foundation. Published by Elsevier.","name":"copyright","label":"Copyright"}]}}